AMGEN INC
For the period ended Mar 31, 2026. Filed May 1, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 1, 2026
AMGN$465.23+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
DEFINED TERMS AND PRODUCTSii
Defined Terms and Products
Defined terms
We use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related, as well as names of other companies, which are provided below.
| Term | Description |
|---|---|
| 2017 Tax Act | Tax Cuts and Jobs Act of 2017 |
| 340B Program | Federal 340B Drug Pricing Program |
| AAV | anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis |
| AOCI | accumulated other comprehensive income (loss) |
| AstraZeneca | AstraZeneca plc |
| BeOne | BeOne Medicines Ltd. (formerly BeiGene, Ltd.) |
| CDER | FDA’s Center for Drug Evaluation and Research |
| ChemoCentryx | ChemoCentryx, Inc. |
| CMS | Centers for Medicare & Medicaid Services |
| DILI | drug-induced liver injury |
| DSC | Drug Safety Communication |
| EMA | European Medicines Agency |
| EPS | earnings per share |
| EU | European Union |
| FDA | U.S. Food and Drug Administration |
| Fitch | Fitch Ratings, Inc. |
| GAAP | U.S. generally accepted accounting principles |
| HHS | U.S. Department of Health and Human Services |
| Horizon | Horizon Therapeutics plc |
| IPR&D | in-process research and development |
| IRA | Inflation Reduction Act of 2022 |
| IRS | Internal Revenue Service |
| July MFN Letter | Letter dated July 31, 2025, by the Administration to certain pharmaceutical manufacturers, including Amgen |
| Later-Stage Clinical Programs | R&D expenses incurred in or related to phase 2 and phase 3 clinical programs intended to result in registration of a new product or a new indication for an existing product primarily in the United States or the EU |
| MD&A | management’s discussion and analysis |
| MFN | Most-Favored-Nations |
| MFN EO | Most-Favored-Nations Prescription Drug Pricing Executive Order |
| Moody’s | Moody’s Investors Service, Inc. |
| NIH | National Institutes of Health |
| OB3 | P.L. 119-21, commonly known as The One Big Beautiful Bill Act signed into law on July 4, 2025 |
| OECD | Organisation for Economic Co-operation and Development |
| PBM | pharmacy benefit manager |
| PDAB | Prescription Drug Affordability Board |
| R&D | research and development |
| RANKL | receptor activator of nuclear factor kappa-B ligand |
| RAR | Revenue Agent Report |
| ROW | rest of world |
| S&P | Standard & Poor’s Financial Services LLC |
| SEC | U.S. Securities and Exchange Commission |
| SG&A | selling, general and administrative |
| SOFR | Secured Overnight Financing Rate |
| U.S. Treasury | U.S. Department of the Treasury |
| UTB | unrecognized tax benefit |
| VBDS | vanishing bile duct syndrome |
ii
Products
The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are provided below.
| Term | Description |
|---|---|
| ACTIMMUNE | ACTIMMUNE® (interferon gamma-1b) |
| Aimovig | Aimovig® (erenumab-aooe) |
| AMJEVITA/AMGEVITA | AMJEVITA® (adalimumab-atto)/AMGEVITA™ (adalimumab) |
| Aranesp | Aranesp® (darbepoetin alfa) |
| AVSOLA | AVSOLA® (infliximab-axxq) |
| BKEMV/BEKEMV | BKEMV® (eculizumab-aeeb)/BEKEMV™ (eculizumab) |
| BLINCYTO | BLINCYTO® (blinatumomab) |
| BUPHENYL | BUPHENYL® (sodium phenylbutyrate) |
| Corlanor | Corlanor® (ivabradine) |
| ENBREL | Enbrel® (etanercept) |
| EPOGEN | EPOGEN® (epoetin alfa) |
| EVENITY | EVENITY® (romosozumab-aqqg) |
| IMDELLTRA/IMDYLLTRA | IMDELLTRA® (tarlatamab-dlle)/IMDYLLTRA™ (tarlatamab) |
| IMLYGIC | IMLYGIC® (talimogene laherparepvec) |
| KANJINTI | KANJINTI® (trastuzumab-anns) |
| KRYSTEXXA | KRYSTEXXA® (pegloticase) |
| KYPROLIS | KYPROLIS® (carfilzomib) |
| LUMAKRAS/LUMYKRAS | LUMAKRAS®/LUMYKRAS™ (sotorasib) |
| MariTide | Maridebart cafraglutide (MariTide™) |
| MVASI | MVASI® (bevacizumab-awwb) |
| Neulasta | Neulasta® (pegfilgrastim) |
| NEUPOGEN | NEUPOGEN® (filgrastim) |
| Nplate | Nplate® (romiplostim) |
| Otezla | Otezla® (apremilast) |
| Parsabiv | Parsabiv® (etelcalcetide) |
| PAVBLU | PAVBLU® (aflibercept-ayyh) |
| PENNSAID | PENNSAID® (diclofenac sodium topical solution) 2% |
| PROCYSBI | PROCYSBI® (cysteamine bitartrate) |
| Prolia | Prolia® (denosumab) |
| QUINSAIR | QUINSAIR® (levofloxacin) |
| RAVICTI | RAVICTI® (glycerol phenylbutyrate) |
| RAYOS | RAYOS® (prednisone) |
| Repatha | Repatha® (evolocumab) |
| RIABNI | RIABNI® (rituximab-arrx) |
| Sensipar/Mimpara | Sensipar®/Mimpara™ (cinacalcet) |
| TAVNEOS | TAVNEOS® (avacopan) |
| TEPEZZA | TEPEZZA® (teprotumumab-trbw) |
| TEZSPIRE | TEZSPIRE® (tezepelumab-ekko) |
| UPLIZNA | UPLIZNA® (inebilizumab-cdon) |
| Vectibix | Vectibix® (panitumumab) |
| WEZLANA/WEZENLA | WEZLANA® (ustekinumab-auub)/WEZENLA™ (ustekinumab) |
| XGEVA | XGEVA® (denosumab) |
iii
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.